Bueso L, Gago F, López R, Rodríguez N, Vigo S

Language: Spanish
References: 6
Page: 16-18
PDF size: 51.25 Kb.

ABSTRACT

An important Latin American Oncology meeting that took place in Miami, Florida, where oncologists from several countries in the region (Mexico, Brazil, Colombia, Argentina, Uruguay, Chile, etc.) participated. This consensus meeting had the objective of sharing the current knowledge of clinicians and researchers about different kinds of neoplasia and their updated clinical management according to the latest criteria and guidelines developed by the main research groups around the world, in order to present a useful document for these specialists in their daily work with cancer patients. With the purpose of exploring and discussing six different important oncological topics and establish some useful guidelines, participants were divided in six working groups with the following themes: 1) guidelines for the management of bone loss secondary to cancer treatment; 2) guidelines for the management of hormone dependent breast cancer; 3) guidelines for the management of bone metastases with zoledronic acid in lung cancer patients; 4) guidelines for the management of bone metastases secondary to breast cancer with zoledronic acid; 5) guidelines for the management of breast cancer with extended adjuvant therapy, and 6) guidelines for the management of GIST (gastrointestinal stoma tumors). This document presents the analysis of the hormone dependent breast cancer updated treatment according to the corresponding discussion group. Hormone-dependent breast cancer has a high morbidity and mortality rates all over the world and challenges the women’s health and quality of life around the world. Nowadays, the use of new aromatase inhibitors (letrozol, anastrozol, etc.) has open a new window for the achievement of better clinical outcomes, and it is starting to replace tamoxifen as the first line treatment with very promising results.

REFERENCES

1. Goss PE, et al. Emerging Role of Aromatase Inhibitors in the Adjuvant Setting. American J Clin Oncology (CCT) 26 (4 suppl:s)27-s33, 2003.

2. Goss PE, Yow O, et al. An overview of aromatase inhibitors in the treatment of metastatic breast cancer. Current Oncology. Vol. 8. No. 2. pp. 1-9.

3. Lonning PE. Pharmacology of new aromatase inhibitors. The breast 1996; 5:202-8

4. Ellis M, Coop A, Singh B, et al Letrozole is more effective neoadyuvant endocrine therapy than tamoxifen for ErbB1 and/ or ErbB2 positive, estrogen receptor positive primary breast cancer: evidence from a phase III randomize trial. J Clin Oncol 2001, 19: 3808-16.

5. Goss PE, Strasser-Weippl K. Prevention strategies with aromatase inhibitors. Clin Cancer Res 2004. Jan 1; 10(1 Pt 2):3728-98.

6. Carsten Rose. A Comparison of the Efficacy of Aromatase Inhibitors in Second Line Treatment of Metastatic Breast Cancer. Am J Oncol (CCT) 26 (4 suppl 1) S9-S16, 2003.